Get the Stockscreener App
28.75
1.45%
0.41
Pre-market:
27.88
-0.87
-3.03%
Assembly Biosciences Inc stock is traded at $28.75, with a volume of 244.65K.
It is up +1.45% in the last 24 hours and up +3.16% over the past month.
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
See More
Previous Close:
$28.34
Open:
$28.33
24h Volume:
244.65K
Relative Volume:
2.04
Market Cap:
$456.91M
Revenue:
$71.10M
Net Income/Loss:
$-6.38M
P/E Ratio:
-23.94
EPS:
-1.2009
Net Cash Flow:
$-39.84M
1W Performance:
+8.41%
1M Performance:
+3.16%
6M Performance:
-22.69%
1Y Performance:
+112.65%
1-Day Range:
$27.41
$29.05
1-Week Range:
$25.76
$31.89
52-Week Range:
$13.70
$39.70
Assembly Biosciences Inc Stock (ASMB) Company Profile
Name
Assembly Biosciences Inc
Sector
Industry
Phone
(833) 409-4583
Address
TWO TOWER PLACE, SOUTH SAN FRANCISCO
Compare ASMB vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ASMB
Assembly Biosciences Inc
|
28.75 | 450.40M | 71.10M | -6.38M | -39.84M | -1.2009 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Assembly Biosciences Inc Stock (ASMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-24-25 | Initiated | Citizens JMP | Mkt Outperform |
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Mar-25-25 | Initiated | Guggenheim | Buy |
| Sep-20-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-13-21 | Initiated | H.C. Wainwright | Neutral |
| Sep-02-21 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-23-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Nov-06-20 | Downgrade | Jefferies | Buy → Hold |
| Oct-19-20 | Initiated | Truist | Buy |
| Oct-16-19 | Initiated | Mizuho | Buy |
| Nov-19-18 | Initiated | Leerink Partners | Outperform |
| Oct-08-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Aug-08-18 | Initiated | Robert W. Baird | Outperform |
| Apr-13-18 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Jan-05-18 | Initiated | B. Riley FBR, Inc. | Neutral |
| Nov-08-17 | Initiated | Jefferies | Buy |
| May-30-17 | Initiated | Chardan Capital Markets | Buy |
View All
Assembly Biosciences Inc Stock (ASMB) Latest News
Assembly Biosciences closes $115 million stock offering - Investing.com UK
Assembly Biosciences Completes Significant Equity Offering Financing - TipRanks
Assembly Biosciences closes $115 million stock offering By Investing.com - Investing.com Australia
Assembly Biosciences Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - The Manila Times
Assembly Biosciences (ASMB) completes $115M stock and pre-funded warrant sale - Stock Titan
Assembly Bio raises $115M for viral and liver drug clinical work - Stock Titan
Assembly Biosciences Surges 6.9% as Buyers Defend Key Support Level (ASMB)BPI Bull Correction - Newser
Assembly Biosciences prices $100M equity offering - MSN
Zoom Upbeat Q1 Results, Joins Lionsgate Studios, Ross Stores And Other Big Stocks Moving Higher On Friday - Sahm
Key facts: Assembly Biosciences Offers; ABI-6250 Expanded to PBC/PSC - TradingView
Assembly Biosciences (NASDAQ: ASMB) raises ~$93M; 3.36M shares, 415K pre-funded warrants - Stock Titan
Assembly Biosciences (ASMB) Expands Clinical Focus on Liver Dise - GuruFocus
Assembly Biosciences (ASMB) Prices $100M Offering to Support Cli - GuruFocus
Assembly Biosciences (NASDAQ: ASMB) launches stock and pre-funded warrant offering - Stock Titan
Assembly Biosciences prices $100 million stock offering at $26.50 - Investing.com UK
Assembly Biosciences Expands ABI-6250 Clinical Development to Target Cholestatic Liver Diseases Including PBC and PSC - Minichart
Assembly Biosciences expands ABI-6250 development to liver diseases By Investing.com - Investing.com Nigeria
Assembly Biosciences expands ABI-6250 development to liver diseases - Investing.com UK
Assembly Biosciences prices $100 million stock offering at $26.50 By Investing.com - Investing.com South Africa
Assembly Biosciences prices $100 million offering - The Pharma Letter
Assembly Biosciences Shares Up Amid Expansion of ABI-6250 Drug Development - Moomoo
Assembly Biosciences stock surges on PBC and PSC expansion plan By Investing.com - Investing.com Australia
Assembly Biosciences stock surges on PBC and PSC expansion plan - Investing.com
Assembly Biosciences Expands ABI-6250 Liver Disease Program - TipRanks
Assembly Biosciences Prices $100 Million Offering - Moomoo
Assembly Bio (NASDAQ: ASMB) plans Phase 2 ABI-6250 trials in HDV, PBC and PSC - Stock Titan
Assembly Biosciences Plans Phase 2 Study of ABI-6250 in Cholestatic Liver Diseases PBC and PSC to Begin in Q1 2027 - Quiver Quantitative
Assembly Biosciences Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases - The Manila Times
Assembly Biosciences Announces Pricing of $100 Million Offering of Common Stock and Pre-Funded Warrants - marketscreener.com
Biotech Assembly Bio prices $100M sale to fund viral, liver drug work - Stock Titan
Experimental liver drug ABI-6250 heads to Phase 2 tests in PBC and PSC - Stock Titan
Crude Oil Edges Higher; US Consumer Sentiment Falls In May - Sahm
Trading Systems Reacting to (ASMB) Volatility - Stock Traders Daily
Assembly Biosciences, Inc.Common Stock (ASMB) Stock Price, News, Quote & History - FinancialContent
Assembly Biosciences Touts HSV, Hepatitis D Catalysts at BofA Conference - Yahoo Finance
Assembly Biosciences Shares Caution As Healthcare Growth Expectations Fade - Kalkine Media
These Analysts Just Made A Huge Downgrade To Their Assembly Biosciences, Inc. (NASDAQ:ASMB) EPS Forecasts - simplywall.st
Assembly Biosciences to present HDV drug data at EASL congress - Investing.com
Assembly Biosciences to present HDV drug data at EASL congress By Investing.com - Investing.com Australia
Assembly Biosciences to Present Topline Phase 1a Data on Hepatitis Delta Virus Entry Inhibitor ABI-6250 at the EASL Congress 2026 - The Manila Times
Assembly Biosciences to Present Topline Clinical Data on ABI-6250, a Novel Oral Hepatitis D Virus Entry Inhibitor, at EASL Congress 2026 - Quiver Quantitative
Oral hepatitis D entry inhibitor brings Phase 1a data to Barcelona - Stock Titan
MarketsMedicine Hat News - FinancialContent
Paradigm entities and Dr. Asefaw report holdings in Assembly Biosciences (ASMB) - Stock Titan
Analysts Have Lowered Expectations For Assembly Biosciences, Inc. (NASDAQ:ASMB) After Its Latest Results - simplywall.st
Assembly Biosciences to Present at the BofA Securities 2026 Global Health Care Conference - Weekly Voice
Biotech Assembly Bio to speak at BofA 2026 Global Health Care Conference - Stock Titan
We're Hopeful That Assembly Biosciences (NASDAQ:ASMB) Will Use Its Cash Wisely - Yahoo Finance
Guggenheim Maintains Assembly Biosciences(ASMB.US) With Buy Rating, Maintains Target Price $43 - Moomoo
Assembly Biosciences 1Q Loss/Shr 54c >ASMB - Moomoo
Assembly Biosciences Inc Stock (ASMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):